by | Dec 1, 2019 | Hawkins, William, Hotchkiss, Richard, Spitzer, Dirk
— WUSTL Technology 007646
Technology Description
Researchers at Washington University in St. Louis (WUSTL) have developed a novel TRAIL (TNF-related apoptosis inducing ligand)-based anticancer drug platform, designated TR3. TRAIL has potent and specific apoptotic activity against tumor cells. Thus,…
by | Nov 27, 2019 | Boles, Kent, Colonna, Marco
— Target: T Cell Immunoreceptor with Ig and ITIM domains, a.k.a. WUCAM
Notes: Clone available is 4E1.2. Used in flow cytometry and functional studies.
Mouse IgG3 was generated by immunizing BALB/c mice with WUCAMFLAG-Baf3 cells. This can be used to study T cell-dependent antibody responses.
Publication: A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
by | Nov 27, 2019 | Luke, Clifford, Pak, Stephen, Silverman, Gary, Thomas, Brian
— Plasmids were generated with the NHX-2 promoter, to restrict gene expression to the C. elegans intestinal cells, driving C. elegans genes or targeting peptides, known to target different subcellular organelles, fused to a C. elegans optimized mOrange2 fluorescent protein (CemOrange2). These expressi…
by | Nov 27, 2019 | Ellebedy, Ali
— These are recombinant human monoclonal antibodies that are directed against two conserved internal proteins of the influenza virus.
by | Nov 27, 2019 | Luke, Clifford, Pak, Stephen, Silverman, Gary, Thomas, Brian
— Plasmids were generated with the NHX-2 promoter, to restrict gene expression to the C. elegans intestinal cells, driving C. elegans genes or targeting peptides, known to target different subcellular organelles, fused to a C. elegans optimized mOrange2 fluorescent protein (CemOrange2). These expressi…